Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib + PD-1 maintenance in advanced gastric cancer
NCT06888037Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Mar 2025
- Primary completion
- Mar 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fruquintinib in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Ruijin Hospital. Primary endpoint: One-year progression-free survival rate at 1 year. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
fruquintinib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06888037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06888037.